title: Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.
abstract: OBJECTIVE
  To determine overall survival of patients treated for a first relapse of FIGO stage III ovarian cancer, outside of randomized trial, with a long term follow-up and to identify prognostic factors.
  
  
  METHODS
  A consecutive series of 108 patients treated for a first relapse of a FIGO stage III ovarian cancer was retrospectively included from December 1999 to November 2004. Each patient was treated with platinum-based chemotherapy in case of late (>6 months) relapse and with salvage chemotherapy without platinum in case of <6 months relapse. For statistical analysis the studied parameters were age, histological subtype, the completeness of initial surgery, disease-free period, localization of the relapse, clinical response to second-line chemotherapy, the completeness of secondary cytoreductive surgery (SCS) when it was performed.
  
  
  RESULTS
  Median follow-up from the first relapse was 40 months. From the 108 patients, 35 underwent SCS. Median overall survival from the first relapse was 13 months in case of no SCS or non-optimal SCS and 35 months for patient with an optimal SCS (p = 0.006). In a multivariate analysis age, disease-free period, the clinical presentation of the relapse, completeness of SCS and response to second line chemotherapy appeared to be independent prognostic factors.
  
  
  CONCLUSIONS
  Prognostic factors of ovarian cancer relapse are directly or indirectly linked with the feasibility of a complete SCS. Thus in the case of an ovarian cancer relapse, the feasibility of SCS must be considered in order to give the patient the best chance to experience its complete removal.
authors.affiliation: Department of Surgical Oncology, Institut de Cancérologie de l'Ouest - Cancer Center Rene Gauducheau, Nantes Saint Herblain, France. jm-classe@nantes.fnclcc.fr
authors.forename: J M
authors.initials: JM
authors.lastname: Classe
authors.forename: I
authors.initials: I
authors.lastname: Jaffre
authors.forename: J S
authors.initials: JS
authors.lastname: Frenel
authors.forename: V
authors.initials: V
authors.lastname: Bordes
authors.forename: M
authors.initials: M
authors.lastname: Dejode
authors.forename: F
authors.initials: F
authors.lastname: Dravet
authors.forename: G
authors.initials: G
authors.lastname: Ferron
authors.forename: F
authors.initials: F
authors.lastname: Marchal
authors.forename: D Berton
authors.initials: DB
authors.lastname: Rigaud
authors.forename: D
authors.initials: D
authors.lastname: Loussouarn
authors.forename: L
authors.initials: L
authors.lastname: Campion
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010052:Ovariectomy / Q000379:methods*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents